MAGESTIC Trial: MiRNA in Detecting Active Germ Cell Tumors in Early Suspected and MetastaTIC Disease Trial

Recruiting at 1 trial location

Overseen By Ileana Aldana

Age: Any Age

Sex: Male

Trial Phase: Academic

Sponsor: University of Southern California

No Placebo Group All trial participants will receive the active study treatment (no placebo)

Compensation: Varies

Number of Visits: Unknown

418 Participants Needed

Trial Summary

What is the purpose of this trial?

This study evaluates the accuracy of blood-based biomarker testing to predict the presence of active testicular cancer.

Research Team

Siamak Daneshmand, MD

Principal Investigator

University of Southern California

Eligibility Criteria

Inclusion Criteria

Retroperitoneal lymphadenopathy must conform to an RPLND template.

The primary tumor was removed by a radical inguinal orchiectomy, and the pathology results are indicative of either seminoma or non-seminomatous germ cell tumors.

You are suffering from stage I pure seminoma, isolated retroperitoneal relapse or Stage IIA/B pure seminoma.

Treatment Details

Participant Groups

Group I: Observational Experimental Treatment 1 Intervention

Patients undergo blood sample collection during screening and throughout the study. Patients whose screening blood samples show elevated miRNA-371 proceed to standard RPLND surgery. Patients whose screening blood samples show normal levels of miRNA-371 undergo standard surveillance followed by standard RPLND surgery at the time of elevated miRNA-371 levels. Patients may also have their medical records reviewed.

Who Is Running the Clinical Trial?

University of Southern California

Lead Sponsor

Trials

956

Recruited

1,609,000+

National Cancer Institute (NCI)

Collaborator

Trials

14,080

Recruited

41,180,000+